Short Interest in Lisata Therapeutics, Inc. (NASDAQ:LSTA) Declines By 14.1%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 16,400 shares, a drop of 14.1% from the December 15th total of 19,100 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 25,600 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Lisata Therapeutics in a research note on Wednesday, December 11th.

Lisata Therapeutics Stock Down 0.3 %

Shares of LSTA stock traded down $0.01 during trading hours on Friday, reaching $3.71. 71,879 shares of the stock traded hands, compared to its average volume of 42,044. The business has a fifty day moving average price of $3.03 and a 200 day moving average price of $3.06. Lisata Therapeutics has a 1-year low of $2.19 and a 1-year high of $4.20. The firm has a market capitalization of $31.13 million, a PE ratio of -1.48 and a beta of 1.14.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.16. During the same period last year, the business earned ($0.65) EPS. Research analysts expect that Lisata Therapeutics will post -2.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP grew its position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.